Importantly, D-2HG accumulation and NAPRT hypermethylation that occurs in mutant IDH1/2 cancers could be potential candidates for NAMPT inhibitor trials as they lack NA pathway (Figure 1). This evidence concerns the gene IDH1 and cancer.